Salarius Pharmaceuticals Announces Senior Leadership Changes
Scott Jordan Appointed Chief Business Officer; Mark Rosenblum, Appointed Interim Chief Financial Officer
HOUSTON, Sept. 13, 2019 — Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer today announced the appointment of Scott Jordan to the new role of Chief Business Officer and the appointment of Mark Rosenblum to the position of Executive Vice President Finance and Interim Chief Financial Officer. These changes are intended to enhance Salarius’ focus on financial operations and strategic value creation while its lead clinical programs in Ewing sarcoma and advanced solid tumors continue to advance toward potential data milestones in 2020. Epigenetics refers to the regulatory system that affects gene expression and can cause cancer. Drugs that are able to safely modify the activity of these epigenetic regulators may correct the gene changes that are driving the disease.